Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-073522
Filing Date
2025-05-16
Accepted
2025-05-16 16:05:23
Documents
1
Period of Report
2025-05-15

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3882
  Complete submission text file 0000950170-25-073522.txt   5440
Mailing Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125
Business Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125 206.588.0256
ATOSSA THERAPEUTICS, INC. (Issuer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O VANTAGE CONSULTING GROUP, INC. 3500 PACIFIC AVENUE VIRGINIA BEACH VA 23451
Business Address
Finn Jonathan (Reporting) CIK: 0001981595 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35610 | Film No.: 25959052